Red herring prospectus

Vivid Seats Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Public Warrants

Retrieved on: 
Thursday, June 30, 2022

The Company has been advised that 11,366,727 public warrants, or approximately 62.7% of the outstanding public warrants, were validly tendered and not validly withdrawn prior to the expiration of the Offer and Consent Solicitation.

Key Points: 
  • The Company has been advised that 11,366,727 public warrants, or approximately 62.7% of the outstanding public warrants, were validly tendered and not validly withdrawn prior to the expiration of the Offer and Consent Solicitation.
  • The Warrant Amendment required the consent of holders of at least 65% of the outstanding public warrants.
  • Pursuant to the Consent Solicitation, the Company received the approval of approximately 62.7% of the outstanding public warrants to the Warrant Amendment.
  • Certain statements made in this document are forward-looking statements with respect to the Offer and Consent Solicitation, the services offered by Vivid Seats and the markets in which it operates and Vivid Seats projected future results.

BLUE OWL CAPITAL ANNOUNCES PRICING OF SECONDARY OFFERING OF CLASS A COMMON SHARES

Retrieved on: 
Thursday, June 2, 2022

NEW YORK, June 2, 2022 /PRNewswire/ -- Blue Owl Capital Inc. (the "Company" or "Blue Owl Capital") (NYSE: OWL) today announced the pricing of the previously announced underwritten secondary offering by NBSH Blue Investments II, LLC (the "Selling Stockholder") of 10,698,180 shares of the Company's Class A common stock at a price to the public of $11.50 per share (the "Offering").

Key Points: 
  • NEW YORK, June 2, 2022 /PRNewswire/ -- Blue Owl Capital Inc. (the "Company" or "Blue Owl Capital") (NYSE: OWL) today announced the pricing of the previously announced underwritten secondary offering by NBSH Blue Investments II, LLC (the "Selling Stockholder") of 10,698,180 shares of the Company's Class A common stock at a price to the public of $11.50 per share (the "Offering").
  • Blue Owl is not selling any of its Class A common stock in the Offering and will not receive any proceeds from the Offering, including from any exercise by the underwriters of their option to purchase additional ordinary shares.
  • In addition, none of Blue Owl's directors or officers sold any shares of Class A common stock in this offering.
  • Blue Owl Capital undertakes no duty to update any forward-looking statements made herein.

StrikeReady Honored with 2021 'ASTORS' Homeland Security Award for Best Threat Intelligence Solution

Retrieved on: 
Monday, December 6, 2021

StrikeReady , a cloud-based security operations and management company, announced today that it was named a 2021 'ASTORS' Homeland Security Award for Best Threat Intelligence Solution by American Security Today.

Key Points: 
  • StrikeReady , a cloud-based security operations and management company, announced today that it was named a 2021 'ASTORS' Homeland Security Award for Best Threat Intelligence Solution by American Security Today.
  • View the full release here: https://www.businesswire.com/news/home/20211206005116/en/
    StrikeReady Honored with 2021 'ASTORS' Homeland Security Award for Best Threat Intelligence Solution (Graphic: Business Wire)
    We are honored to be recognized in American Security Todays distinguished 2021 ASTORS Awards Program, said Yasir Khalid, CEO of StrikeReady.
  • In addition, we have made tracking of active in-the-wild attacks available for free to all of our threat intelligence community through StrikeReady Recon .
  • StrikeReady has won numerous awards and mentions in the short time that it has been in existence, including American Security Today 'ASTORS' Homeland Security Award 2021, Security Today's Product of the Year Award 2021, Globee's Disruptor Award 2021, CB Insights 2021 Cyber Defender, and 2020 Red Herring's Top 100 North America Award.

Green Plains Announces Upsizing and Pricing of its Common Stock Offering

Retrieved on: 
Thursday, August 5, 2021

The company has also granted the underwriters in the common stock offering a 30-day option to purchase up to an additional 712,500 shares of its common stock on the same terms and conditions solely to cover over-allotments.

Key Points: 
  • The company has also granted the underwriters in the common stock offering a 30-day option to purchase up to an additional 712,500 shares of its common stock on the same terms and conditions solely to cover over-allotments.
  • The company intends to use the net proceeds from the common stock offering for growth investments to further accelerate its downstream development opportunities.
  • The Company also owns a 48.9% limited partner interest and a 2.0% general partner interest in Green Plains Partners LP.
  • Green Plains assumes no obligation to update any such forward-looking statements, except as required by law.

Green Plains Announces Proposed Offering of $150 million of Common Stock

Retrieved on: 
Wednesday, August 4, 2021

The company also intends to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional $22.5 million of the shares of common stock offered solely to cover over-allotments.

Key Points: 
  • The company also intends to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional $22.5 million of the shares of common stock offered solely to cover over-allotments.
  • The company expects to use the net proceeds from the offering for growth investments to further accelerate its downstream development opportunities.
  • The Company also owns a 48.9% limited partner interest and a 2.0% general partner interest in Green Plains Partners LP.
  • Green Plains assumes no obligation to update any such forward-looking statements, except as required by law.

RxSight, Inc. Announces Closing of Initial Public Offering and Partial Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Wednesday, August 4, 2021

With the addition of the partial exercise of the underwriters option to purchase additional shares, the total number of shares sold by RxSight in the offering increased to 8,248,594 shares of common stock, and the aggregate gross proceeds to RxSight before deducting underwriting discounts and commissions and offering expenses, were approximately $132 million.

Key Points: 
  • With the addition of the partial exercise of the underwriters option to purchase additional shares, the total number of shares sold by RxSight in the offering increased to 8,248,594 shares of common stock, and the aggregate gross proceeds to RxSight before deducting underwriting discounts and commissions and offering expenses, were approximately $132 million.
  • Shares of RxSights common stock began trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol RXST.
  • J.P. Morgan Securities LLC and BofA Securities, Inc. acted as joint book-running managers of the offering and as representatives of the underwriters.
  • This press release contains forward-looking statements, including with respect to the proposed initial public offering.

Cytek Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, August 2, 2021

With the addition of the full exercise of the underwriters option to purchase additional shares, the total number of shares sold in this offering increased to 16,749,330, and the aggregate gross proceeds to Cytek, before deducting underwriting discounts and commissions and estimated offering expenses, were $237 million.

Key Points: 
  • With the addition of the full exercise of the underwriters option to purchase additional shares, the total number of shares sold in this offering increased to 16,749,330, and the aggregate gross proceeds to Cytek, before deducting underwriting discounts and commissions and estimated offering expenses, were $237 million.
  • The offering consisted of 13,949,401 shares issued and sold by Cytek, and 2,799,929 shares sold by the selling stockholders named in the prospectus.
  • Cytek did not receive any proceeds from the sale of shares by the selling stockholders.
  • Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

RxSight, Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, July 30, 2021

ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share.

Key Points: 
  • ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share.
  • The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • This press release contains forward-looking statements, including with respect to the proposed initial public offering.

Dole plc Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, July 30, 2021

Dole plc, a newly created company formed for the combination of Total Produce plc and Dole Food Company, Inc., announced today the pricing of its initial public offering of 25,000,000 ordinary shares at a price of $16.00 per share.

Key Points: 
  • Dole plc, a newly created company formed for the combination of Total Produce plc and Dole Food Company, Inc., announced today the pricing of its initial public offering of 25,000,000 ordinary shares at a price of $16.00 per share.
  • The ordinary shares are being offered by Dole plc for total gross proceeds of $400 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, the underwriters have been granted a 30-day option to purchase up to an additional 3,750,000 ordinary shares at the initial public offering price, less underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Deutsche Bank Securities and Davy are acting as lead book-running managers for the offering.

Clarios Announces Postponement of Plans for Initial Public Offering and Listing

Retrieved on: 
Thursday, July 29, 2021

Clarios will reassess the market conditions in the coming months and will keep the market informed.

Key Points: 
  • Clarios will reassess the market conditions in the coming months and will keep the market informed.
  • A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective.
  • These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
  • We partner with our aftermarket and original equipment customers to meet increasing market demand for smarter applications, on a global scale.